Imidazolines and pancreatic hormone secretion

Annals of the New York Academy of Sciences

Volumn 881, Issue , 1999, Pages 217-228

  Morgan, Noel G ^a   Chan, Sue L F ^a   Mourtada, Mirna ^a   Monks, Lara K ^a   Ramsden, Christopher A ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIBENZOLINE; IDAZOXAN; IMIDAZOLINE; INSULIN; PANCREAS HORMONE; POTASSIUM CHANNEL;

BINDING SITE; CONFERENCE PAPER; DRUG BINDING; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS SECRETION;

EID: 0032799426     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09364.x     Document Type: Conference Paper

References (41)

1. Schulz, A. & A. Hasselblatt. 1988. Phentolamine, a deceptive tool to investigate sympathetic nervous control of insulin release. Naunyn-Schmiedeberg's Arch. Pharmacol. 337: 637-643.
2. Schulz, A. & A. Hasselblatt. 1989. An insulin-releasing property of imidazoline derivatives is not limited to compounds that block α-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 340: 321-327.
3. Smith, M. & B. L. Furman. 1988. Augmentation of glucose-induced insulin secretion by pertussis toxin vaccine, phentolamine and benextramine; involvement of mechanisms additional to prevention of the inhibitory actions of catecholamines in rats. Acta Endocrinol. 188: 89-96.
4. + channels in mouse pancreatic β-cells. Br. J. Pharmacol. 101: 115-120.
5. + channels. Eur. J. Pharmacol. 176: 97-101.
6. +-ATP channels in insulin secreting cells. Eur. J. Pharmacol. 204: 41-48.
7. + channels in pancreatic β-cells. Br. J. Pharmacol. 107: 8-14.
8. Berdeu, D., R. Gross, G. Ribes, M.-M. Loubatiēres-Mariani & G. Bertrand. 1994. Effects of imidazolines and derivatives on insulin secretion and vascular resistance in perfused rat pancreas. Eur. J. Pharmacol. 254: 119-125.
9. 2 receptors. Eur. J. Pharmacol. 262: 41-48.
10. Zaitsev, S. V., A. M. Efanov, A. M. Efanova, O. Larsson, C.-G. Ostenson, G. Gold, P.-O. Berggren & S. Efendic. 1996. Imidazoline compounds stimulate insulin release by inhibition of K-ATP channels and interaction with the exocytotic machinery. Diabetes 45: 1610-1618.
11. Efanova, I. B., S. V. Zaitsev, A. M. Efanov, C.-G. Ostenson, P.-O. Berggren & S. Efendic. 1996. Effects of imidazoline derivative RX871024 on insulin, glucagon and somatostatin secretion from isolated perfused rat pancreas. Diabetologia 39: A235.
12. Mourtada, M., S. A. Smith & N. G. Morgan. 1997. Insulin secretagogues with an imidazoline structure inhibit arginine-induced glucagon secretion from isolated rat islets of Langerhans. Biochem. Biophys. Res. Comm. 236: 162-166.
13. Kawazu, S., M. Suzuki, T. Watanabe; & J. Ishii. 1987. Studies of midaglizole (DG-5128): A new type of oral hypoglycemic drug in healthy subjects. Diabetes 36: 216-220.
14. Broadstone, V. L., M. A. Pfeifer, V. Bajaj, J. I. Stagner & E. Samols. 1987. α-Adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes 36: 932-937.
15. Wang, X., F. Rondu, A. Lamouri, R. Dokhan, S. Marc, E. Touboul, B. Pfeiffer, D. Manechez, P. Renard, B. Guardiola-Lemaitre, J.-J. Godfroid, A. Ktorza & L. Penicaud. 1996. Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes. J. Pharmacol. Exp. Ther. 278: 82-89.
16. Berdeu, D., R. Puech, G. Ribes, M.-M. Loubatieres-Mariani & G. Bertrand. 1997. Antazoline increases insulin secretion and improves glucose tolerance in rats and dogs. Eur. J. Pharmacol. 324: 233-239.
17. Pele-Tounian, A., X. Wang, F. Rondu, A. Lamouri, E. Touboul, S. Marc, R. Dokhan, B. Pfeiffer, D. Manechez, P. Renard, B. Guardiola-Lemaitre, J.-J. Godfroid, L. Penicaud & A. Ktorza. 1998. Potent antihyperglycaemic property of a new imidazoline derivative S-22068 (PMS 847) in a rat model of NIDDM. Br. J. Pharmacol. 124: 1591-1596.
18. 2-adrenoceptors and imidazoline binding sites in control of insulin secretion. Clin. Sci. 85: 671-677.
19. Dunne, M. J., E. A. Harding, J. H. Jagger, P. E. Squires, R. Liang, C. Kane, R. F. L. James & N. J. London. 1995. Potassium channels, imidazolines, and insulin-secreting cells. Ann. N.Y. Acad. Sci. 763: 243-261.
20. Morgan, N. G. 1994. Adrenoceptors and imidazoline binding sites in the endocrine pancreas as targets for anti-hyperglycaemic drugs. Exp. Opin. Invest. Drugs 3: 561-569.
21. Morgan, N. G., S. L. F. Chan, C. A. Brown & E. Tsoli. 1995. Characterization of the imidazoline binding site involved in regulation of insulin secretion. Ann. N.Y. Acad. Sci. 763: 361-373.
22. Molderings, G. J. 1997. Imidazoline receptors: Basic knowledge, recent advances and future prosepects for therapy and diagnosis. Drugs Future 22: 757-772.
23. Eglen, R. M., A. L. Hudson, D. A. Kendall, D. J. Nutt, N. G. Morgan, V. G. Wilson & M. P. Dillon. 1998. Seeing through a glass darkly: Casting light on imidazoline I sites. Trends Pharmacol. Sci. 19: 381-390.
24. Brown, C. A., A. C. Loweth, S. A. Smith & N. G. Morgan. 1993. Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites. Br. J. Pharmacol. 108: 312-317
25. Remaury, A. & H. Paris. 1992. The insulin-secreting cell line, RINm5F, expresses alpha-2D adrenoceptor and nonadrenergic idazoxan binding sites. J. Pharmacol. Exp. Ther. 260: 417-426.
26. ATP channels in pancreatic B-cells. Naunyn-Schmeideberg's Arch. Pharmacol. 356: 410-417.
27. 2-sites. Br. J. Pharmacol. 112: 1065-1070.
28. Ishida-Takahashi, A., M. Horie, Y. Tsuura, H. Ishida, T. Ai & S. Sasayama. 1996. Block of pancreatic ATP-sensitive potassium chanels and insulinotropic action by the antiarrhythmic agent, cibenzoline. Br. J. Pharmacol. 117: 1749-1755.
29. + channel block by sulfonylurea in pancreatic beta-cells. Am. J. Physiol. 274: E38-E44.
30. ATP channel subunits. Neuron 18: 827-838.
31. ATP channels. Physiol. Rev. 78: 227-245.
32. Brown, C. A., S. L. F. Chan, M. R. Stillings, S. A. Smith & N. G. Morgan. 1993. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline RX801080. Br. J. Pharmacol. 110: 1017-1022.
33. Chan, S. L. F., A. L. Pallett, J. Clews, C. A. Ramsden & N. G. Morgan. 1997. Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with σ receptors. Eur. J. Pharmacol. 323: 241-244.
34. Chan, S. L. F., A. L. Pallett, J. Clews, C. A. Ramsden, J. C. Chapman, C. Kane, M. J. Dunne & N. G. Morgan. 1998. Characterization of new efaroxan derivatives for use in purification of imidazoline-binding sites. Eur. J. Pharmacol. 355: 67-76.
35. ATP channels is mediated by Kir6.2. Proc. Natl. Acad. Sci. USA 94: 1716-1720.
36. 2-adrenoceptor antagonist efaroxan involves a novel, stereoselective, binding site. Eur. J. Pharmacol. 230: 375-378.
37. Shepherd, R. M., M. N. Hasmi, C. Kane, P. E. Squires & M. J. Dunne. 1996. Elevation of cytosolic calcium by imidazolines in mouse islets of Langerhans: Implications for stimulus-response coupling of insulin release. Br. J. Pharmacol. 119: 911-916.
38. Efanov, A. M., S. V. Zaitsev, I. B. Efanova, S. Zhu, C.-G. Ostenson, P.-O. Berggren & S. Efendic. 1998. Signaling and sites of interaction for RX-871024 and sulfonlyurea in the stimulation of insulin release. Am. J. Physiol. 274: E751-E757.
39. Mourtada, M., S. A. Smith & N. G. Morgan. 1998. Effector systems involved in the insulin secretory responses to efaroxan and RX871024 in rat islets of Langerhans. Eur. J. Pharmacol. In press.
40. 2+ in pancreatic B-cells. Eur. J. Pharmacol. 298: 279-286.
41. Le Brigand, L., A. Virsolvy, K. Peyrollier, D. Manechez, J.-J. Godfroid, B. Guardiola-Lemaitre & D. Bataille. 1997. Stimulation of insulin release from the MIN6 cell line by a new imidazoline compound, S21663: Evidence for the existence of a novel imidazoline site in β-cells. Br. J. Pharmacol. 122: 786-791.